{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/NBP/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T12:24:51.352Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":10792,"canonical_name":"NovaBridge Biosciences","cik":"0001778016","uei":null,"lei":null,"duns":null,"ticker":"NBP"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":26},"count":26,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-09-11","url_slug":"/sec/cik-0001778016/4/0002109966-26-000008","accession_number":"0002109966-26-000008","importance":30},{"ts":"2026-09-09","kind":"sec.insider.s","reporter":"Cao Sean Wuxiong","title":"Chief Bus. Development Officer","shares":107978,"price_per_share":0.74,"usd_value":79904,"security_title":"Ordinary Shares","importance":35.07990372},{"ts":"2026-07-17","kind":"sec.filing","form_type":"6-K","title":"6-K — NovaBridge Biosciences — 2026-07-17","url_slug":"/sec/cik-0001778016/6-k/0001193125-26-306688","accession_number":"0001193125-26-306688","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"3","title":"3 — NovaBridge Biosciences — 2026-07-08","url_slug":"/sec/cik-0001778016/3/0002024011-26-000004","accession_number":"0002024011-26-000004","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-07-08","url_slug":"/sec/cik-0001778016/4/0002024011-26-000006","accession_number":"0002024011-26-000006","importance":30},{"ts":"2026-07-07","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-07-07","url_slug":"/sec/cik-0001778016/4/0002114309-26-000005","accession_number":"0002114309-26-000005","importance":30},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Xu Cong Claire","title":"SVP, Clinical Development","shares":4485,"price_per_share":0.89,"usd_value":3992,"security_title":"Ordinary Shares","importance":35.00399165},{"ts":"2026-07-06","kind":"sec.insider.4485","reporter":"Xu Cong Claire","title":"SVP, Clinical Development","shares":4485,"price_per_share":0.89,"usd_value":3992,"security_title":"Ordinary Shares","importance":15.00399165},{"ts":"2026-07-04","kind":"sec.insider.12432","reporter":"Xu Cong Claire","title":"SVP, Clinical Development","shares":12432,"price_per_share":null,"usd_value":0,"security_title":"Ordinary Shares","importance":15},{"ts":"2026-07-04","kind":"sec.insider.m","reporter":"Xu Cong Claire","title":"SVP, Clinical Development","shares":12432,"price_per_share":null,"usd_value":0,"security_title":"Ordinary Shares","importance":15},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-06-30","url_slug":"/sec/cik-0001778016/4/0001885756-26-000005","accession_number":"0001885756-26-000005","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"6-K","title":"6-K — NovaBridge Biosciences — 2026-06-29","url_slug":"/sec/cik-0001778016/6-k/0001193125-26-286812","accession_number":"0001193125-26-286812","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-06-24","url_slug":"/sec/cik-0001778016/4/0002109966-26-000004","accession_number":"0002109966-26-000004","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-06-22","url_slug":"/sec/cik-0001778016/4/0002089237-26-000006","accession_number":"0002089237-26-000006","importance":30},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Dennis Phillip Andrew","title":"Chief Medical Officer","shares":8494,"price_per_share":0.66,"usd_value":5606,"security_title":"Ordinary Shares","importance":35.00560604},{"ts":"2026-06-17","kind":"sec.insider.m","reporter":"Dennis Phillip Andrew","title":"Chief Medical Officer","shares":23695,"price_per_share":null,"usd_value":0,"security_title":"Ordinary Shares","importance":15},{"ts":"2026-06-16","kind":"sec.filing","form_type":"20-F/A","title":"20-F/A — NovaBridge Biosciences — 2026-06-16","url_slug":"/sec/cik-0001778016/20-f-a/0001778016-26-000006","accession_number":"0001778016-26-000006","importance":30},{"ts":"2026-06-16","kind":"sec.filing","form_type":"6-K","title":"6-K — NovaBridge Biosciences — 2026-06-16","url_slug":"/sec/cik-0001778016/6-k/0001193125-26-271793","accession_number":"0001193125-26-271793","importance":30},{"ts":"2026-06-16","kind":"sec.filing","form_type":"6-K","title":"6-K — NovaBridge Biosciences — 2026-06-16","url_slug":"/sec/cik-0001778016/6-k/0001778016-26-000005","accession_number":"0001778016-26-000005","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-06-02","url_slug":"/sec/cik-0001778016/4/0002114309-26-000003","accession_number":"0002114309-26-000003","importance":30},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Xu Cong Claire","title":"SVP, Clinical Development","shares":3494,"price_per_share":3.94,"usd_value":13766,"security_title":"Ordinary Shares","importance":35.01376636},{"ts":"2026-05-30","kind":"sec.insider.m","reporter":"Xu Cong Claire","title":"SVP, Clinical Development","shares":9382,"price_per_share":null,"usd_value":0,"security_title":"Ordinary Shares","importance":15},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — NovaBridge Biosciences — 2026-05-18","url_slug":"/sec/cik-0001778016/4/0001193125-26-228889","accession_number":"0001193125-26-228889","importance":30},{"ts":"2026-05-14","kind":"sec.form144","reporter":"Cao Sean Wuxiong","title":"Officer, CHIEF BUSINESS DEVELOPMENT OFFICER","shares":9304,"usd_value":18534,"security_title":"COMMON STOCK","approx_sale_date":"2026-05-14","accession_number":"0001973379-26-000176","importance":40.003706882},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Cao Sean Wuxiong","title":"See Remarks","shares":21399,"price_per_share":1.99,"usd_value":42584,"security_title":"Ordinary Shares","importance":35.04258401},{"ts":"2026-05-14","kind":"sec.filing","form_type":"144","title":"144 — NovaBridge Biosciences — 2026-05-14","url_slug":"/sec/cik-0001778016/144/0001973379-26-000176","accession_number":"0001973379-26-000176","importance":30}]}